LB - Mattressland 0425 Temperpedic

Home | Real Estate Search | Classifieds | Place an Ad | Public Notices | Galleries | Obituaries | Subscriber Services | Kingman Digital | Contact Us
Kingman Daily Miner | Kingman, Arizona

home : features : features April 28, 2016


10/29/2013 6:00:00 AM
New therapies offer hope to breast cancer patients

Dr. Hamdy Mohtaseb
Kingman Physician


Treatment of breast cancer has been rapidly advancing within the field of oncology. There are different lines of therapy available for this disease, depending on specific cancer subtypes and characteristics.

Breast cancer is a multi-disease entity based on some patient-related as well as tumor-related factors. These factors include the menopausal status of the patient, estrogen and progesterone receptors status, and human epithelial receptor 2 on cancer cells. Some other factors include tumor invasion and grade and type of cancer cell (ductal vs. lobular).

Over the years, treatment of breast cancer consisted of surgery followed by chemotherapy with or without radiation therapy in patients. Targeted therapies are now available against many cancers that represent more effective, less toxic treatment when compared to conventional chemotherapy.

The idea came through the discovery of receptors that are present on cancer cells that promote cancer but are not present nor induce cancer on normal cells. In breast cancer, for example, by targeting certain receptors and pathways through molecular therapies, we are able to specifically achieve direct cancer-cell killing with minimal toxicity in most cases.

One of the most fascinating therapeutic strategies in oncology is the one that targets HER2 receptors. Approximately 20 percent of breast cancers over express HER2, which historically is associated with increased recurrence and an overall worse prognosis compared to HER2 negative breast cancer. However, the discovery of HER2 directed therapy is a paradigm shift that has revolutionized the natural history with increased survival despite a patient having this type of breast cancer. It has abrogated the poor prognosis of this type of breast cancer into a more chronic and favorable disease.

Until recently, there were two anti-HER2 medications, Herceptin and the oral medication Lapatinib. Both are approved for treatment of HER2 positive breast cancer in combination with chemotherapy. We may also use this target therapy, Herceptin, as monotherapy without chemotherapy in patients with limited or asymptomatic advanced breast cancer.

Because HER2 positive breast cancer is historically an unfavorable disease, many patients eventually progress and become resistant to Herceptin and Lapatinib.

Two new generations of anti-HER2 therapies that have proven to be a great benefit in this situation were added this year. In February, the Food and Drug Administration approved a novel anti-HER2 therapy, T-DM1 (Kadcyla), for patients who progress during six months of Herceptin therapy in early (adjuvant) status and those who progressed in the advanced (metastatic) setting.

The approval was based on a landmark EMILIA study of 978 patients who showed significant improvement in disease progression, mortality rate, and overall response rate (44 vs. 31 percent) with less side effects compared to the other HER2 medication Lapatinib with chemotherapy.

That study was followed by another fascinating research project where 808 patients with HER2 metastatic breast cancer showed an improved outcome using another new anti-HER2 therapy, Pertuzumab (Perjeta), in combination with Herceptin and chemotherapy compared to Herceptin or chemotherapy alone. The overall response rate was 80 percent versus 69 percent, which led to the approval of Pertuzumab by the FDA as a new generation of anti-HER2 therapy.

The FDA approved Perjeta on Oct. 2 in combination with other anti-HER2 therapies before surgery in early-stage breast cancer that carries HER2, which could be a remarkable step forward into eradicating this type of breast cancer.

The advantage of treating breast cancer as well as other cancers with these targeted therapies is that the therapies only attack cells that carry those particular receptors, thus preserving or sparing normal tissue from any bad effects.

Chemotherapy, on the other hand, does not differentiate between cancer and normal cells.

There is now a trend of getting away from chemotherapy in treating cancer in general. The reality is we are already at the point where patients with cancer could be treated successfully with these biologic, targeted therapies rather than the more toxic modalities. We are already seeing steps in that direction in lung, kidney and prostate cancers, as well as in leukemia and lymphoma and, in the near future, breast cancer.

If you have any questions on this topic, please contact our offices either in Kingman (928) 681-1234 or Fort Mohave (928) 770-4560. We will be happy to address your questions promptly.

ICT - Trotters RV

    Most Viewed     Recently Commented
•   Hard legal lessons faced by accused in home invasion case (2226 views)

•   20-year sentence possible for murder in Yucca (1548 views)

•   Alleged theft among counts returned by grand jury (874 views)

•   Important measures await votes on May 17 special ballot (788 views)

•   McCain fundraiser arrested following drug raid (689 views)



Reader Comments

Posted: Wednesday, October 30, 2013
Article comment by: just a fact

Dr. Mohtaseb is an excellent oncologist. He is a knowledge and caring doctor.



Article Comment Submission Form
Comments are not posted immediately. Submissions must adhere to our Use of Service Terms of Use agreement. Rambling or nonsensical comments may not be posted. Comments are limited to Facebook character limits. In order for us to reasonably manage this feature we may limit excessive comment entries.
Submit an Article Comment
First Name:
Required
Last Name:
Required
Telephone:
Required
Email:
Required
Comment:
Required
Passcode:
Required
Anti-SPAM Passcode Click here to see a new mix of characters.
This is an anti-SPAM device. It is not case sensitive.
   


Advanced Search

HSE - We want to hear from you
Kingman Chamber News
House Ad- Dining Guide
Auto Racing Upickem
Find more about Weather in Kingman, AZ
Click for weather forecast






Find it Features Blogs Milestones Extras Submit Other Publications Local Listings
Real Estate Search | Classifieds | Place an Ad | Find Kingman Jobs | Kingman Chamber | e-News | Contact Us | RSS | Site Map
LB - House 928 Media Lab 0426

© Copyright 2016 Western News&Info, Inc.® The Kingman Daily Miner is the information source for Kingman and surrounding area communities in Northern Arizona. Original content may not be reprinted or distributed without the written permission of Western News&Info, Inc.® Kingman Daily Miner Online is a service of WNI. By using the Site, kdminer.com ®, you agree to abide and be bound by the Site's terms of use and Privacy Policy, which prohibit commercial use of any information on the Site. Click here to email your questions, comments or suggestions. Kingman Daily Miner Online is a proud publication of Western News&Info, Inc.® All Rights Reserved.


Software © 1998-2016 1up! Software, All Rights Reserved